GEN1079 Clinical Trials (2026): 1 Studies for Advanced Solid Tumors
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
1 GEN1079 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 1 indication (including Advanced Solid Tumors) and 121 total planned enrollment. 1 GEN1079 clinical trial is actively recruiting at 3 U.S. sites across 3 states. Most recent activity: NCT07387068 (Jan 2031).
Where to Participate: All GEN1079 Trial Sites in the U.S. (3 sites across 3 states)
Every actively recruiting GEN1079trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| CT | Yale University | New Haven06520 | NCT07387068 | Map |
| MI | START Midwest, LLC | Grand Rapids49546 | NCT07387068 | Map |
| NY | START New York | Lake Success11042 | NCT07387068 | Map |
GEN1079 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | Total |
|---|---|---|
| P1 | 1 | 1 |
Recruiting GEN1079 clinical trials (1)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | P1 | Advanced Solid Tumors | 121 | Apr 2026 |
All GEN1079 trials (1)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors | P1 | recruiting | 121 | Genmab | Apr 2026 |
GEN1079 clinical trials: frequently asked questions
- How many GEN1079 clinical trials are there?
- 1 GEN1079 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants.
- Are GEN1079 clinical trials recruiting in 2026?
- Yes — 1 GEN1079 trial is actively recruiting in 2026, with 3 U.S. sites across 3 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is GEN1079 being studied for?
- GEN1079 is being studied for Advanced Solid Tumors. The trials are grouped by indication on this page.
- What phase is GEN1079 in?
- GEN1079 clinical trials span 1 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors GEN1079 clinical trials?
- The lead sponsor across the most GEN1079 trials is Genmab. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming GEN1079as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: